期刊文献+

11962例枸橼酸西地那非(万艾可)不良反应报告分析 被引量:8

Adverse Drug Reactions Caused by Sildenafil Citrate (Viagra):Analysis of 11 962 Cases
下载PDF
导出
摘要 目的:探讨枸橼酸西地那非(万艾可)上市8年来可疑不良反应发生的特点,对临床规范用药提供有益借鉴。方法:查阅世界卫生组织药物不良反应数据库,检索并分析和比较万艾可的不良反应报告。结果:万艾可药物不良反应报告主要集中在心血管、神经、消化等系统,各个系统不良反应表现形式各异。严重不良反应如死亡、心肌梗死、心绞痛及异常勃起的报告率逐年下降。结论:应该继续规范万艾可的临床应用,以尽量减少死亡、异常勃起等严重不良反应的发生,该药物对肺动脉高压、神经再生、女性性功能障碍等病症的新型应用研究应该谨慎进行。 OBJECTIVE: To discuss the characteristics of the ADRs (adverse drug reaction ) caused by Viagra (Sildenafil Citrate) in 8 years ever since it has been put into market so as to offer beneficial references for clinical standard medication. METHODS: Viagra- induced ADR cases were collected from WHO ADR database and which were analyzed statistically. RESULTS: Cardiovascular system, nervous system and digestive system were predominantly involved in Viagra- induced ADRs, which manifested differently. The incidences of serious Viagra - induced ADRs such as death, myocardial infarction, angina pectoris and priapism have been decreasing year by year. CONCLUSION: The standard use of Viagra should be emphasized to minimize the incidences of serious ADRs including death and priapism etc. The research on the new use of Viagra in the treatment of pulmonary hypertension, neural regeneration and female sexual disturbance etc should be carried out cautiously.
出处 《中国医院用药评价与分析》 2009年第5期391-393,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 枸橼酸西地那非 药品不良反应 Sildenafil citrate Adverse drug reaction (ADR)
  • 相关文献

参考文献10

  • 1Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999[J]. BJU Ira, 2004, 93(6) :796.
  • 2Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafll [J]. Ann Pharmacother, 2002,36(7 - 8) : 1 129.
  • 3Jackson G, Gllies H, Osterloh I. Past, present, and future: a 7 - year update of Viagra (sildenafil citrate) [ J]. Int J Clin Pract, 2005, 59(6): 680.
  • 4陈亮,张素敏,张承绪.磷酸二酯酶5型抑制剂与α-受体阻滞剂的相互作用研究进展[J].中国药物警戒,2008,5(3):162-165. 被引量:1
  • 5Vitezic D. A risk - benefit assessment of sildenafil in the treatment of erectile dysfunction [ J ]. Drug Saf, 2001, 24 (4) : 255.
  • 6Cohen JS. Should Patients be Given an Initial Low Test Dose of Sildenafil[J]? Drug Saf, 2000, 23 (1): 1.
  • 7Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents[J] . J Manag Care Pharm , 2005, 11(2):151.
  • 8Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors[J]. Int J Clin Pract, 2006, 60(8) : 967.
  • 9Kloner RA. Cardiovascular effects of the 3 phosphodiesterase - 5 inhibitors approved for the treatment of erectile dysfunction[J].Circulation, 2004,110(19) :3149.
  • 10郝树伟,徐震雷,贺占举,姜辉,胡佩诚.勃起功能障碍患者性治疗的临床应用研究[J].中华男科学杂志,2008,14(6):538-541. 被引量:1

二级参考文献26

  • 1郝树伟,徐震雷,贺占举,姜辉,胡佩诚.影响ED性治疗临床推广应用的相关因素分析[J].中华男科学杂志,2006,12(9):811-813. 被引量:3
  • 2[1]Kloner R A,Brown M,Prisant L M,et al.Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy[J].Am J Hypertens,2001,14:70 -73.
  • 3[2]Picketing T G,Mancia G,Glasser D B,et al.Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treat ments[J].Am J Hypertens,2002,15(suppl 1):A55-A56.
  • 4[3]Conti C R,Pepine C J,Sweeney M.Efficacy and safety of sildenafil citrate in the treatment of ED in patients with ischemic heart disease[J].Am J Cardiol,1999,83(suppl 5A):29C-34C.
  • 5[4]Kloner R A,Jarow J P.Erectile dysfunction and sildenafil citrate and cardiologists[J].Am J Cardiol,1999,83:576 -582.
  • 6[5]Jackson G,Benjamin N,Jackson N,et al..Effects of sildenafil citrate on human hemodynamics[J].Am J Cardiol,1999,83(suppl):13C-20C.
  • 7[6]Product monograph for Levitra (vardenafil hydrochloride).West Haven,CT:Bayer Health Care and Research Triangle Park[M].NC:Glaxo Smith Kline,2003.
  • 8[7]Emmick J T,Stuewe S R,Mitchell M.Overview of the cardiovascular effects of tadalafil[J].Eur Heart J,2002,4:H32-H47.
  • 9[8]Kloner R A,Mitchell M,Emmick J T.Cardiovascular effects of tadalafil[J].Am J Cardiol,2003,92(suppl):37M-46M.
  • 10[9]DeBusk R,Drory Y,Goldstein I,et al.Management of sexual dysfunction in patients with cardiovascular disease:recommendations of the Princeton Consensus Panel[J].Am J Cardiol,2000,86:175-181.

同被引文献50

  • 1HOU Wen-bin1,2,3,XIAO Xue-feng1,GUO Wei4,ZHANG Tie-jun2,3 1.Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China 2.Research Center for Modern Chinese Materia Medica,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China 3.State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China 4.Xiehe Pharmaceutical Group Company,Shenyang 110179,China.Advances in Studies on Chemistry,Pharmacological Effect,and Pharmacokinetics of Eurycoma longifolia[J].Chinese Herbal Medicines,2011,3(3):186-195. 被引量:5
  • 2林岫芳,周智涓,陈剑.冠心病患者的性生活要有度[J].心血管病防治知识,2004(4):48-48. 被引量:3
  • 3Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999[J]. BJUlnt,2004 ,93(6):796.
  • 4Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil [ J ]. Ann Pharmacother, 2002,36 ( 7 - 8 ) : 1 129.
  • 5Jackson G, Gllies H, Osterloh I. Past, present, and future: a 7 - year update of Viagra ( sildenafil citrate) [ J ]. lnt J Clin Pract, 2005, 59 (6) : 680.
  • 6Tran D, Howes LG. Cardiovascular safety of sildenafil [J]. Drug Saf ,2003 ,26 (7): 453.
  • 7Vitezic D. A risk - benefit assessment of aildenafil in the treatment of erectile dysfunction [ J ]. Drug Saf, 2001,24 (4) : 255.
  • 8Cohen JS. Should patients be given an initialLow test dose of sildenafil[ J] ? Drug Saf, 2000,23 ( 1 ) : 1.
  • 9Campbell HE . Clinical monograph for drug formulary review: erectile dysfunction agents [ J ]. J Manag Care Pharm,2005,11 (2) :151.
  • 10Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors [ J ]. Int J Clin Pract, 2006, 60 (8) :967.

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部